Eintrag weiter verarbeiten
Clinical trials for multiple sclerosis: Outcome measures and impact on cognitive function
Gespeichert in:
| Zeitschriftentitel: | Clinical and Experimental Neuroimmunology |
|---|---|
| Personen und Körperschaften: | |
| In: | Clinical and Experimental Neuroimmunology, 10, 2019, 3, S. 169-179 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Ochi, Hirofumi Ochi, Hirofumi |
|---|---|
| author |
Ochi, Hirofumi |
| spellingShingle |
Ochi, Hirofumi Clinical and Experimental Neuroimmunology Clinical trials for multiple sclerosis: Outcome measures and impact on cognitive function Neurology (clinical) Immunology and Microbiology (miscellaneous) Immunology Neuroscience (miscellaneous) |
| author_sort |
ochi, hirofumi |
| spelling |
Ochi, Hirofumi 1759-1961 1759-1961 Wiley Neurology (clinical) Immunology and Microbiology (miscellaneous) Immunology Neuroscience (miscellaneous) http://dx.doi.org/10.1111/cen3.12527 <jats:title>Abstract</jats:title><jats:p>Multiple sclerosis (<jats:styled-content style="fixed-case">MS</jats:styled-content>) is a complex immune‐mediated disease characterized by recurrent demyelinating episodes of the central nervous system, which is the most common disabling neurological disease of young people. Cognitive impairment is common and one of the disabling symptoms of <jats:styled-content style="fixed-case">MS</jats:styled-content>, resulting in reduced quality of life. This often emerges early in the disease and is independent of physical disability; however, it is more prevalent in progressive disease. With the advent of a number of disease‐modifying drugs, including agents with high efficacy at reducing inflammatory activity, patients with <jats:styled-content style="fixed-case">MS</jats:styled-content> can receive more efficacious treatment. Although the currently available disease‐modifying drugs have been shown to reduce the inflammatory disease activity, their effects on the neurodegenerative aspect or cognitive functions are still unclear. Cognitive rehabilitation and physical exercise are promising strategies to prevent cognitive decline or improve brain function. Beneficial effects of these interventions have been reported, but the evidence is still sparse. The present review article describes the clinical trial data on interventions for cognitive impairment in <jats:styled-content style="fixed-case">MS</jats:styled-content>.</jats:p> Clinical trials for multiple sclerosis: Outcome measures and impact on cognitive function Clinical and Experimental Neuroimmunology |
| doi_str_mv |
10.1111/cen3.12527 |
| facet_avail |
Online |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9jZW4zLjEyNTI3 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9jZW4zLjEyNTI3 |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-D161 |
| imprint |
Wiley, 2019 |
| imprint_str_mv |
Wiley, 2019 |
| issn |
1759-1961 |
| issn_str_mv |
1759-1961 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
ochi2019clinicaltrialsformultiplesclerosisoutcomemeasuresandimpactoncognitivefunction |
| publishDateSort |
2019 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Clinical and Experimental Neuroimmunology |
| source_id |
49 |
| title |
Clinical trials for multiple sclerosis: Outcome measures and impact on cognitive function |
| title_unstemmed |
Clinical trials for multiple sclerosis: Outcome measures and impact on cognitive function |
| title_full |
Clinical trials for multiple sclerosis: Outcome measures and impact on cognitive function |
| title_fullStr |
Clinical trials for multiple sclerosis: Outcome measures and impact on cognitive function |
| title_full_unstemmed |
Clinical trials for multiple sclerosis: Outcome measures and impact on cognitive function |
| title_short |
Clinical trials for multiple sclerosis: Outcome measures and impact on cognitive function |
| title_sort |
clinical trials for multiple sclerosis: outcome measures and impact on cognitive function |
| topic |
Neurology (clinical) Immunology and Microbiology (miscellaneous) Immunology Neuroscience (miscellaneous) |
| url |
http://dx.doi.org/10.1111/cen3.12527 |
| publishDate |
2019 |
| physical |
169-179 |
| description |
<jats:title>Abstract</jats:title><jats:p>Multiple sclerosis (<jats:styled-content style="fixed-case">MS</jats:styled-content>) is a complex immune‐mediated disease characterized by recurrent demyelinating episodes of the central nervous system, which is the most common disabling neurological disease of young people. Cognitive impairment is common and one of the disabling symptoms of <jats:styled-content style="fixed-case">MS</jats:styled-content>, resulting in reduced quality of life. This often emerges early in the disease and is independent of physical disability; however, it is more prevalent in progressive disease. With the advent of a number of disease‐modifying drugs, including agents with high efficacy at reducing inflammatory activity, patients with <jats:styled-content style="fixed-case">MS</jats:styled-content> can receive more efficacious treatment. Although the currently available disease‐modifying drugs have been shown to reduce the inflammatory disease activity, their effects on the neurodegenerative aspect or cognitive functions are still unclear. Cognitive rehabilitation and physical exercise are promising strategies to prevent cognitive decline or improve brain function. Beneficial effects of these interventions have been reported, but the evidence is still sparse. The present review article describes the clinical trial data on interventions for cognitive impairment in <jats:styled-content style="fixed-case">MS</jats:styled-content>.</jats:p> |
| container_issue |
3 |
| container_start_page |
169 |
| container_title |
Clinical and Experimental Neuroimmunology |
| container_volume |
10 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792333300353728515 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:10:32.013Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Clinical+trials+for+multiple+sclerosis%3A+Outcome+measures+and+impact+on+cognitive+function&rft.date=2019-08-01&genre=article&issn=1759-1961&volume=10&issue=3&spage=169&epage=179&pages=169-179&jtitle=Clinical+and+Experimental+Neuroimmunology&atitle=Clinical+trials+for+multiple+sclerosis%3A+Outcome+measures+and+impact+on+cognitive+function&aulast=Ochi&aufirst=Hirofumi&rft_id=info%3Adoi%2F10.1111%2Fcen3.12527&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792333300353728515 |
| author | Ochi, Hirofumi |
| author_facet | Ochi, Hirofumi, Ochi, Hirofumi |
| author_sort | ochi, hirofumi |
| container_issue | 3 |
| container_start_page | 169 |
| container_title | Clinical and Experimental Neuroimmunology |
| container_volume | 10 |
| description | <jats:title>Abstract</jats:title><jats:p>Multiple sclerosis (<jats:styled-content style="fixed-case">MS</jats:styled-content>) is a complex immune‐mediated disease characterized by recurrent demyelinating episodes of the central nervous system, which is the most common disabling neurological disease of young people. Cognitive impairment is common and one of the disabling symptoms of <jats:styled-content style="fixed-case">MS</jats:styled-content>, resulting in reduced quality of life. This often emerges early in the disease and is independent of physical disability; however, it is more prevalent in progressive disease. With the advent of a number of disease‐modifying drugs, including agents with high efficacy at reducing inflammatory activity, patients with <jats:styled-content style="fixed-case">MS</jats:styled-content> can receive more efficacious treatment. Although the currently available disease‐modifying drugs have been shown to reduce the inflammatory disease activity, their effects on the neurodegenerative aspect or cognitive functions are still unclear. Cognitive rehabilitation and physical exercise are promising strategies to prevent cognitive decline or improve brain function. Beneficial effects of these interventions have been reported, but the evidence is still sparse. The present review article describes the clinical trial data on interventions for cognitive impairment in <jats:styled-content style="fixed-case">MS</jats:styled-content>.</jats:p> |
| doi_str_mv | 10.1111/cen3.12527 |
| facet_avail | Online |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9jZW4zLjEyNTI3 |
| imprint | Wiley, 2019 |
| imprint_str_mv | Wiley, 2019 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-D161 |
| issn | 1759-1961 |
| issn_str_mv | 1759-1961 |
| language | English |
| last_indexed | 2024-03-01T14:10:32.013Z |
| match_str | ochi2019clinicaltrialsformultiplesclerosisoutcomemeasuresandimpactoncognitivefunction |
| mega_collection | Wiley (CrossRef) |
| physical | 169-179 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Clinical and Experimental Neuroimmunology |
| source_id | 49 |
| spelling | Ochi, Hirofumi 1759-1961 1759-1961 Wiley Neurology (clinical) Immunology and Microbiology (miscellaneous) Immunology Neuroscience (miscellaneous) http://dx.doi.org/10.1111/cen3.12527 <jats:title>Abstract</jats:title><jats:p>Multiple sclerosis (<jats:styled-content style="fixed-case">MS</jats:styled-content>) is a complex immune‐mediated disease characterized by recurrent demyelinating episodes of the central nervous system, which is the most common disabling neurological disease of young people. Cognitive impairment is common and one of the disabling symptoms of <jats:styled-content style="fixed-case">MS</jats:styled-content>, resulting in reduced quality of life. This often emerges early in the disease and is independent of physical disability; however, it is more prevalent in progressive disease. With the advent of a number of disease‐modifying drugs, including agents with high efficacy at reducing inflammatory activity, patients with <jats:styled-content style="fixed-case">MS</jats:styled-content> can receive more efficacious treatment. Although the currently available disease‐modifying drugs have been shown to reduce the inflammatory disease activity, their effects on the neurodegenerative aspect or cognitive functions are still unclear. Cognitive rehabilitation and physical exercise are promising strategies to prevent cognitive decline or improve brain function. Beneficial effects of these interventions have been reported, but the evidence is still sparse. The present review article describes the clinical trial data on interventions for cognitive impairment in <jats:styled-content style="fixed-case">MS</jats:styled-content>.</jats:p> Clinical trials for multiple sclerosis: Outcome measures and impact on cognitive function Clinical and Experimental Neuroimmunology |
| spellingShingle | Ochi, Hirofumi, Clinical and Experimental Neuroimmunology, Clinical trials for multiple sclerosis: Outcome measures and impact on cognitive function, Neurology (clinical), Immunology and Microbiology (miscellaneous), Immunology, Neuroscience (miscellaneous) |
| title | Clinical trials for multiple sclerosis: Outcome measures and impact on cognitive function |
| title_full | Clinical trials for multiple sclerosis: Outcome measures and impact on cognitive function |
| title_fullStr | Clinical trials for multiple sclerosis: Outcome measures and impact on cognitive function |
| title_full_unstemmed | Clinical trials for multiple sclerosis: Outcome measures and impact on cognitive function |
| title_short | Clinical trials for multiple sclerosis: Outcome measures and impact on cognitive function |
| title_sort | clinical trials for multiple sclerosis: outcome measures and impact on cognitive function |
| title_unstemmed | Clinical trials for multiple sclerosis: Outcome measures and impact on cognitive function |
| topic | Neurology (clinical), Immunology and Microbiology (miscellaneous), Immunology, Neuroscience (miscellaneous) |
| url | http://dx.doi.org/10.1111/cen3.12527 |